


SAXOCELL[®] e.V.

LIVING DRUGS

Shaping the Future of Medicine

GENE & CELL THERAPIES MADE IN GERMANY

INFO EVENT | MAY 13TH | 3-4 PM CET



Cell and Gene Therapies have the potential to save lives

The Emily Whitehead Story



- 2010: Leukemia (ALL) diagnosis in childhood
- Multiple relapses
- Refractory, untreatable

- 2012: Participation in **experimental CAR-T cell therapy*** (first patient worldwide)
- Dramatic side effects, but complete response
- **Cancer-free** ever since – now over 10 years without relapse

*CD19-CAR-T cells, Kymriah® predecessor


Cell and Gene Therapies are a Game Changer

The Future of treatment for genetic and aggressive tumor diseases




One-must-fit-all solution

Chemotherapy




- Chemical substances
- Regular intake
- Alleviation of symptoms
- Strong side effects
- Not patient-specific

LIVING DRUGS Gene and Cell Therapies




Game changer

Tailored treatment
for specific person & diagnosis



- ✓ **Targeted action** – Targeted attack on cancer cells
- ✓ **Usually a single application** – **Healing** not treating
- ✓ **Long-lasting effect** – Immune cells "remember" tumor
- ✓ **Fewer side effects** – Less damage to healthy cells
- ✓ **Personalized approach** – Adaptable to tumor profile



SaxoCell – the Cluster and the association

Living Drugs „made in Saxony“



For international partners too

For national / German partners

The SaxoCell Cluster





- Funded by German Government
- Winner of the **BMBF/BMFTR Initiative** „Clusters4Future“
 - Selected from 137 applicants nationwide
 - 3 possible funding phases (3 years each)



The SaxoCell e.V. association

- Founded in 2023 in Leipzig
- Long-term **sustainability of the SaxoCell cluster**
- Funded by membership fees, donations & grants






SaxoCell – the Cluster 4 Future for Cell & Gene Therapy

Living Drugs „made in Saxony“




→ **Aim: Development and optimization of safe, effective, and cost-efficient gene and cell therapies (GCT)**

- Network of local partners from science, healthcare, and industry
- Positioning Saxony as a leading hub for gene and cell therapy




Core partners

- **2 Universities** (TU Dresden, Leipzig Uni)
- **1 Fraunhofer** (Cell Therapy & Immunology, Leipzig)
- **3 Hospitals** (Chemnitz, UKL, UKD)
- **23 Industry Partners**



*associated partners



From Promise to Proof

SaxoCell's USPs in Action



With funding from the
Federal Ministry
of Research, Technology
and Space

2 funding periods
15 mio € each

Winner in German
Cluster4 future-
competition



20+ patents

Proven excellence in
preclinical research &
translation to clinic



nature



THE LANCET

75+ papers

High scientific output
in **key technologies**
and visibility



4 spin-offs
2 settlements

Strengthening the
regional economy



Manufacturing of
> 600 CAR-T cell
products in
cooperation with
big pharma

Europe's **leading**
center for GCT &
ATMP-production

Clinical network for cell and gene therapies

Execution of clinical trials at the highest standards



Manufacturing



Fraunhofer IZI

> 650 CAR-T cell products



University hospital Leipzig

300+ CAR-T cell treatments

One of the largest CAR-T cell clinics



University hospital Dresden

≈ 60 CAR-T cell treatments per year



Hospital Chemnitz

50+ CAR-T cell treatments



University hospital Würzburg

100+ CAR-T cell treatments per year



CCCG Jena-Leipzig

> 200 CAR-T cell treatments per year



Hospital Magdeburg

CAR-T cell therapies since 2023



Privileged access to regulatory authorities

Our SaxoCell e.V. Members & Partner Network

From private persons over clusters & associations to cities & institutions



Board of Directors



Martin Bornhäuser
Chairman of the Board



Maren Henneken
Finances



Ilka Henze
Secretariat

Founding members




Industry Partners & Institutions



UNIVERSITÄT
LEIPZIG



Individual members



Join our SaxoCell e.V.

Reasons to join the SaxoCell Network



- Inclusion of partners outside of BMFTR funding
- Start and duration not limited
- Also for international partners

Benefits

GCT Lounge



Connections to science, clinicians, industry & politics in gene and cell therapy

Participation in projects, clinical studies

GCT Knowledge



R&D collaborations, publications, trainings, clinical translation & commercialization

Participation in workshops & meetings and trainings

Funding & GCT Angels



Funding applications, finding project partners & investors

Info about funding opportunities, joint applications


Visibility



Showcase your expertise at events, conferences & communication channels

Website, social media, newsletter, present at SaxoCell events

Advocacy



Be part of policy discussions & shaping policy frameworks

*Round table discussion with stakeholder
Direct line to National Strategy CGT*

How can you get involved and contribute

to shaping the future of medicine



Membership
fees

Sponsorship
Events & Academic Awards

Organizing
joint events

Staff exchanges
& mentoring

Donations

Endowed
Professorships
Research groups & projects

Membership fees

For Industry, Cities, Universities, Hospitals, Academic Institutes, Associations & Individuals



- Membership fees are **annual**

Companies

- Start-ups
 - In the first year after foundation: €50
 - In the second and third year after foundation: €200
- Established companies:
 - Up to 10 employees: €600
 - Up to 50 employees: €1,000
 - Up to 250 employees: €2,000
 - More than 250 employees: €3,000

Cities

- Under 100,000 inhabitants: €8,000
- Over 100,000 inhabitants: €12,500

Universities: €2,500

Hospitals: €2,500

Academic Institutes: €500

Associations or societies: €1,000


Individuals: €100

Students: €20

Non natural persons: €1,000

Associated members: €0

Supporting members: €3,000



Get & stay in touch with us!

SaxoCell contacts, info and socials




CONFERENCE 2026

Penck Hotel Dresden | June 2 - 3, 2026



From Lab to Life: Advancing Cell and Gene Therapies Together
 Join us at the SaxoCell Conference 2026 in Dresden, where leading minds from science, industry, and politics come together to shape the future of safe and accessible cell and gene therapies – bridging innovation and implementation.



Contact Person
 Anthony Ao



Linked in



Newsletter



E-Mail: verein@saxocell.de